#United States #Chicago #American Lung Association #COVID-19 Treatments #healthcare education

American Lung Association's New Campaign on COVID-19 Therapeutics

The American Lung Association (ALA) has recently announced a significant campaign designed to enhance healthcare provider education regarding the therapeutic options available for preventing and treating COVID-19. Respiratory viruses continue to be a major health concern within the United States, with COVID-19 presenting an ongoing challenge that requires proactive measures to protect those at high risk of severe illness and complications.

The Need for Education

Recent data from the U.S. Centers for Disease Control and Prevention (CDC) highlights an alarming reality: during the respiratory virus season spanning from October 2025 to May 2026, it's estimated that between 3.8 to 12.3 million cases of COVID-19 occurred, alongside approximately 250,000 hospitalizations and 41,000 deaths. These statistics underscore the necessity of ongoing public health initiatives as COVID-19 remains a serious threat to public health.

In response to this pressing issue, Harold Wimmer, President and CEO of the American Lung Association, emphasized how paramount it is that healthcare providers stay informed about the latest treatment options. He remarked, "COVID-19 is still a persistent public health issue in the U.S., and preventing disease is especially vital for high-risk individuals. Although advancements in treatments have been made, they are unfortunately underutilized."

Current Therapeutic Options

The campaign's objective is to inform healthcare professionals about various prevention strategies and treatment modalities available to combat COVID-19 effectively. Key treatment options include:
1. Vaccination: The most effective means of mitigating severe illness from COVID-19 is through vaccination, which helps build immunity against the virus.
2. Post-exposure prophylaxis: This includes medications like ensitrelvir for individuals aged 12 and older who are exposed to COVID-19, assisting in preventing the onset of severe disease.
3. Pre-exposure prophylaxis: Pemivibart, an antibody delivered intravenously, is employed to protect those who are moderately or severely immunocompromised.
4. Personal preventive measures: This encompasses practices such as maintaining air quality, good hand hygiene, prompt testing and treatment, and wearing masks, particularly in crowded settings.
5. Treatment for infected individuals: For individuals at higher risk testing positive for COVID-19, initiating treatment promptly is crucial. Healthcare professionals can prescribe oral antiviral medications or intravenous infusions, which can effectively inhibit virus replication and reduce illness duration.

Given the high-risk population, which includes adults aged 65 and older, individuals with chronic lung diseases, and those with various health conditions, proactive engagement in discussing therapeutic options is critical.

Importance of Provider Education

Rocked by the dual blows of under-vaccination and a lagging therapeutic uptake—where less than 15% of eligible patients receive antiviral treatment within five days—there's an urgent need to bridge the information gap. The ALA's campaign is especially aimed at enhancing healthcare providers' knowledge, ensuring they can guide their patients in making informed decisions regarding preventive measures and treatments.

Survey data has revealed that healthcare providers remain the most trusted resources for health information, making it essential for them to recommend vaccinations and engage patients in discussions about their options to mitigate risks from COVID-19. The latest vaccine iterations provide additional layers of protection against severe outcomes, and individuals are encouraged to consult their healthcare providers about their vaccination eligibility.

Conclusion

To improve health outcomes related to COVID-19, the American Lung Association is committed to equipping healthcare providers with up-to-date resources and educational material about therapeutic options. As therapy landscapes evolve, maintaining awareness and understanding of available COVID-19 treatments will be vital in ensuring better health for vulnerable populations. The campaign is generously supported by Shionogi, and for further insights, visit Lung.org/hcp-covid.

For more information on the ongoing efforts and services provided by the American Lung Association, interested individuals can contact them at 1-800-LUNGUSA or visit their official website.

About the American Lung Association

The ALA is dedicated to saving lives by advancing lung health and disease prevention through education, advocacy, and research. Their mission focuses on defeating lung cancer, promoting clean air, improving quality of life for those with lung diseases, and advancing efforts toward a tobacco-free future.